A manufacturer who was traditionally a research organization was making the transition to a become a commercialization company.
The company had limited personnel and economic resources and was looking for a partner to help bring their first commercial product to market.
D2 evaluated the distribution options and given the unique specialty characteristics of the product and the significant patient support requirements conducted a full RFP process to identify the best approach.
This process resulted in the successful selection both a HUB partner and Specialty Pharmacy delivery model.
D2 then turned its attention to conducting a robust round of payer research — including pricing models and advisory boards — to determine both market access considerations and potential pricing and contracting needs.
With D2’s assistance, the manufacturer selected an exclusive distribution model. This model enabled patient centric support without limiting access to patients with this rare disease.
D2’s managed care team provided full MCO coverage and attained virtually 100% market coverage, including largely consistent application of Prior Authorization requirements among many key payers in the market.